Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Camidanlumab tesirine
DRUG
2 trials
Sponsors
ADC Therapeutics S.A.
Conditions
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Refractory Hodgkin Lymphoma
Relapsed Hodgkin Lymphoma
Phase 1
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Completed
NCT02432235
ADC Therapeutics S.A.
Hodgkin Lymphoma, Non-Hodgkin Lymphoma
Start: 2015-10-05
End: 2019-10-24
Updated: 2021-07-13
Phase 2
Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Completed
NCT04052997
ADC Therapeutics S.A.
Refractory Hodgkin Lymphoma, Relapsed Hodgkin Lymphoma
Start: 2019-09-13
End: 2023-01-19
Updated: 2024-03-28
Related Papers
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
2025-12-01
1 citations
CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
Blood
2022-11-15
2 citations
Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Blood
2022-11-15
1 citations
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
2022-11-04
4 citations
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
2022-11-04
2 citations
HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
Clinical Lymphoma Myeloma & Leukemia
2022-09-20
S201: CAMIDANLUMAB TESIRINE: UPDATED EFFICACY AND SAFETY IN AN OPEN-LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
HemaSphere
2022-06-01
14 citations
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
2021-06-01
61 citations
CAMIDANLUMAB TESIRINE EFFICACY AND SAFETY IN AN OPEN‐LABEL, MULTICENTER, PHASE 2 STUDY OF PATIENTS (PTS) WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA (R/R CHL)
Hematological Oncology
2021-06-01
4 citations
Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma
Blood
2020-11-05
19 citations
Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Blood
2020-11-05
3 citations
Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models
Blood
2020-11-04
9 citations
CD25-targeted antibody–drug conjugate depletes regulatory T cells and eliminates established syngeneic tumors via antitumor immunity
Journal for ImmunoTherapy of Cancer
2020-09-01
76 citations
Antibodies to watch in 2020.
2020-01-01
328 citations
ANALYSIS OF CLINICAL DETERMINANTS DRIVING SAFETY AND EFFICACY OF CAMIDANLUMAB TESIRINE (ADCT‐301, CAMI) IN RELAPSED/REFRACTORY (R/R) CLASSICAL HODGKIN LYMPHOMA (CHL)
Hematological Oncology
2019-06-01
8 citations
THE ANTI‐CD25 ANTIBODY‐DRUG CONJUGATE CAMIDANLUMAB TESIRINE (ADCT‐301) PRESENTS A STRONG PRECLINICAL ACTIVITY BOTH AS SINGLE AGENT AND IN COMBINATION IN LYMPHOMA CELL LINES
Hematological Oncology
2019-06-01
6 citations
Phase 1 Study of Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Classical Hodgkin Lymphoma
Blood
2018-11-29
41 citations
Adct-301 (Camidanlumab Tesirine), a Novel Pyrrolobenzodiazepine-Based CD25-Targeting Antibody Drug Conjugate, in a Phase 1 Study of Relapsed/Refractory Non-Hodgkin Lymphoma Shows Activity in T-Cell Lymphoma
Blood
2018-11-29
19 citations
INTERIM DATA FROM THE FIRST CLINICAL STUDY OF ADCT‐301, A NOVEL PYRROLOBENZODIAZAPINE‐BASED ANTIBODY DRUG CONJUGATE, IN RELAPSED/REFRACTORY HODGKIN/NON‐HODGKIN LYMPHOMA
Hematological Oncology
2017-06-01
8 citations